Evolus (EOLS) Receives a Buy from Mizuho Securities
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Uy Ear reiterated a Buy rating on Evolus (EOLS) with a $15.00 price target. This aligns with the stock's Strong Buy consensus and an average price target of $14.50. The analyst covers the Healthcare sector, including Alkermes and Sarepta Therapeutics.
Mizuho Securities analyst Uy Ear reiterated a Buy rating on Evolus today and set a price target of $15.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Sarepta Therapeutics, and Relmada Therapeutics. According to TipRanks, Ear has an average return of 0.1% and a 37.72% success rate on recommended stocks.
Evolus has an analyst consensus of Strong Buy, with a price target consensus of $14.50.